Compare SUPN & CENT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUPN | CENT |
|---|---|---|
| Founded | 2005 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2010 | 1996 |
| Metric | SUPN | CENT |
|---|---|---|
| Price | $42.63 | $39.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $61.75 | $53.00 |
| AVG Volume (30 Days) | ★ 566.5K | 56.6K |
| Earning Date | 11-03-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.41 |
| EPS | N/A | ★ 2.84 |
| Revenue | $392,755,000.00 | ★ $3,129,100,000.00 |
| Revenue This Year | $23.21 | N/A |
| Revenue Next Year | $54.85 | N/A |
| P/E Ratio | ★ N/A | $13.97 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $40.51 | $28.77 |
| 52 Week High | $59.68 | $46.97 |
| Indicator | SUPN | CENT |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 42.96 |
| Support Level | $42.54 | $39.61 |
| Resistance Level | $52.33 | $41.37 |
| Average True Range (ATR) | 1.40 | 0.77 |
| MACD | 0.12 | 0.11 |
| Stochastic Oscillator | 44.81 | 54.42 |
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.